Walsh E E
Dept. of Medicine, Rochester General Hospital, NY 14621.
J Infect Dis. 1994 Aug;170(2):345-50. doi: 10.1093/infdis/170.2.345.
The efficacy of topical immunization with the respiratory syncytial virus (RSV) fusion (F) protein was tested in mice using cholera toxin B chain (CTB) as an adjuvant. The dose of CTB required for the adjuvant effect (as measured by local and systemic antibody stimulation) and protection from viral challenge was > or = 5 micrograms. With this dose, mice immunized intranasally with CTB plus F protein were highly protected from viral replication in the upper and lower respiratory tract. This protection was associated with the induction of mucosal IgA and serum IgG and neutralizing antibody. Addition of parenteral immunization with F protein to the topical vaccination provided protection from viral challenge nearly equivalent to immunization with live RSV intranasally. Topical and parenteral immunization with F protein was not associated with induction of splenic cytotoxic T cells, in contrast to live virus given intranasally.
以霍乱毒素B亚单位(CTB)作为佐剂,在小鼠中测试呼吸道合胞病毒(RSV)融合(F)蛋白局部免疫的效果。产生佐剂效应(通过局部和全身抗体刺激来衡量)以及抵抗病毒攻击所需的CTB剂量≥5微克。使用该剂量时,经鼻内接种CTB加F蛋白的小鼠在上、下呼吸道中受到高度保护,免受病毒复制的影响。这种保护与粘膜IgA、血清IgG以及中和抗体的诱导有关。在局部疫苗接种基础上增加F蛋白的胃肠外免疫,提供的抗病毒攻击保护几乎等同于经鼻内接种活RSV。与经鼻内给予活病毒相反,F蛋白的局部和胃肠外免疫与脾细胞毒性T细胞的诱导无关。